SK Bioscience goes directly to’Tasang’… 740 million money cushion per employee

[사진=연합뉴스]

On the first day of its listing, SK Bioscience succeeded in entering the stock market with’Daesang (the initial price was doubled as the public offering price and then the upper limit price was recorded)’. Due to the surge in stock prices, executives and employees earned an average of more than 700 million won per person and sat on money cushions.

On the 18th, SK Bioscience closed the transaction at 169,000 won, which rose to the price limit (30.00%) after forming an initial price of 130,000 won, which is twice the public offering price. SK Bioscience, which was listed on the day, went directly to’Daesang’ right after opening, and the static and dynamic volatility mitigation device (VI) was activated.

On this day, the trading volume was only 760,000 shares, but as the balance of purchases at the upper limit exceeded 6.3 million shares after the close of the market, expectations for SK Bioscience’s “Dad Sangsang (the upper limit for two days in a row after doubling the initial price)” are also increasing. Last year, SK Biopharm and Kakao Games recorded their upper limit for 3 trading days and 2 consecutive trading days, respectively, after listing. Compared to SK Biopharm and Kakao Games, the number of shares in SK Bioscience is much smaller. SK Bioscience stocks available for circulation are 8.87 million, 7510 shares, which is 11.63% of the issued shares. It is less than last year’s SK Biopharm (13.1%), Kakao Games (20.5%), and Big Hit (19.8%).

After the listing of SK Bioscience, the market cap reached 12,928.5 billion won, ranking 28th in the KOSPI market cap (excluding preferred stocks). It surpassed SK Biopharm (8 trillion 600 billion won) and Big Hit (8 trillion 200 billion won), which were listed and popularized last year. Public offering investors recorded a profit of 2.6 times, gaining 104,000 won per share.

SK Bioscience employees who participated in our stock ownership also sit on money cushions.

In the public offering stock offer, 4.45 million shares were allocated to employee stock ownership, and 4.44 million shares were allocated to employee stock ownership association members. According to the company, 628 members participated, on average, about 7150 shares per person, and the public offering price is 464.75 million won. On this day, the average valuation profit per employee of employee stockholders recorded an average of KRW 743.6 million. However, employee stock ownership stocks cannot be sold for one year after listing. Earlier, there was a precedent that SK Biopharm executives and employees had earned enormous valuation gains and resigned, so the industry is paying attention to whether SK Bioscience will continue to leave the company.